It appears to be a rational strategy to target mitogenic signaling downstream of mutated KRAS and BRAF, since both mutations are prevalent in primary and resistant CRC and the mutations have a negative predictive and prognostic value. The gene discussed is KRAS; the disease is colorectal carcinoma.